Mahi Drugs' API Unit Clears USFDA Audit
· Business · Business Standard
Mahi Drugs' active pharmaceutical ingredient manufacturing unit has successfully cleared an inspection by the United States Food and Drug Administration. The regulatory review evaluated the company's compliance with manufacturing standards and quality controls at the facility. Passing the USFDA audit clears a key regulatory hurdle for the company's pharmaceutical exports to the American market. The inspection report confirms the plant meets the regulatory standards required for commercial distribution in regulated overseas markets.
Why it matters
Regulatory clearance allows Mahi Drugs to maintain and expand its pharmaceutical exports to the United States market without compliance bottlenecks.
Read the original report — Business Standard
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.